Daniel Murokora Murokora
ID: UNCST-2024-R002689
|
Transition To Scale: Using the FREO2 Social Enterprise model and technology to scale up access to Oxygen in Uganda
REFNo: HS1238ES
The aim of this project is to evaluate the impact of a reliable oxygen system on improving a) oxygen reliability and affordability, b) clinical outcomes for children.
With a strong emphasis on clinical and technical training, the project activities should:
a) Improve the availability of oxygen, the detection of hypoxaemia, and the access of a sick child to oxygen when they require it
b) Reduce patient and health system costs of oxygen
c) Understand appropriateness, acceptability, and feasibility of the system in the specific context of health facilities in Western Uganda
|
Uganda |
2021-07-06 |
2024-07-06 |
Medical and Health Sciences |
|
Non-degree Award |
|
Achilles Katamba
ID: UNCST-2019-R000540
|
Evaluation of Xpert® MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second line drugs
REFNo: HS1395ES
Secondary: To evaluate factors for lab uptake o Training needs o Recording and Reporting Needs o Error rates o Proportion of results interpretable o TAT o Work flow,Assess sensitivity and specificity of Xpert® MTB/XDR test in previously stored sputum samples (previously stored) compared to the WHO-endorsed genotypic (MTBDRplus and MTBDRsl) method as a gold standard.,Assess sensitivity and specificity of Xpert® MTB/XDR test in previously stored sputum samples (previously stored) compared to the WHO-endorsed MGIT960 culture-based drug susceptibility method as a gold standard,The main objective is to independently validate the performance of the Xpert® MTB/XDR test for susceptibility testing of MTB among presumptive XDR-TB patients. The test performance indicators will be compared with current standard drug susceptibility test methods including the MGIT 960 liquid culture drug susceptibility (DST) systems, Line probe Assay and Whole genome sequencing. ,
|
Uganda |
2021-07-06 |
2024-07-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Frederick Mubiru Edward
ID:
|
Market Research on Service Delivery Implications for a 4-month Depot Medroxyprogesterone Acetate Subcutaneous (DMPA-SC) Product
REFNo: HS1520ES
1. To explore stakeholder perceptions of client-centered communication needs for a 4-month DMPA-SC product
2. To explore potential barriers and facilitators to the introduction of a 4-month DMPA-SC product
3. To assess implications for data systems, curriculums, training, supervision, logistics, and quality assurance of introducing a 4-month DMPA-SC product
|
Uganda |
2021-07-06 |
2024-07-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Eugene Ruzagira
ID: UNCST-2023-R008282
|
The impact of COVID-19 on primary health care service provision and utilization in Uganda, Sierra Leone and the Democratic Republic of Congo
REFNo: HS1430ES
I.To determine whether COVID-19 is having an impact on the number of people seen at a selection of healthcare facilities for antenatal care, outpatient visits, routine immunisations, family planning and HIV treatment services, using routine health registration data.
II.To document primary healthcare workers’ experiences in providing care during the outbreak and to identify barriers and facilitators to primary health care provision.
III. To estimate the level of exposure to SARS-CoV-2 among healthcare workers by conducting a repeated serosurvey over a period of 4 months.
IV. To document community members’ experiences in accessing primary healthcare during the outbreak and to identify barriers and facilitators to utilisation.
V. To formulate a set of key findings and recommendations in partnership with stakeholders.
|
Uganda |
2021-07-06 |
2024-07-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Ronald Moses Galiwango
ID: UNCST-2024-R015239
|
SARS-CoV-2 infection and variants surveillance in South-central Uganda
(Also known as ‘SARS-CoV-2 surveillance study’)
REFNo: HS1510ES
2.1 Primary objective
To ascertain the burden and transmission patterns of SARS-CoV-2 infection within selected communities in South-central Uganda using rapid antigen tests.
2.2 Secondary objectives
A. To survey for SARS-CoV-2 infection and variants in communities at high-risk of COVID-19 transmission in South-central Uganda through sequencing of specimens positive on both rapid antigen and RT-PCR tests.
B. To determine the acceptability of SARS-CoV-2 antigen rapid diagnostic tests among residents of South-central Uganda.
C. To assess SARS-CoV-2 transmission patterns/dynamics within households and in neighborhoods among communities in South-central Uganda.
D. To assess the burden of prior SARS-CoV-2 infection in South-central Uganda using a validated IgM/IgG antibody test.
|
Uganda |
2021-07-06 |
2024-07-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|